Carl has extensive expertise building commercialization readiness globally for pharmaceutical product launches. He has an unparalleled breadth of expertise in global pharmaceutical supply chain and manufacturing excellence. He offers direction, guidance, best practices and thought leadership to RxC clients. He has overseen the development of end-to-end supply chain strategies, operations excellence, and product launches across the US, Europe and Asia.
Carl has held senior executive positions at Pfizer, Roche, and BMS. He has successfully launched billion dollar drugs, including Pfizer’s Procardia XL, Diflucan, Norvasc, Zithromax, Zoloft & Cardura, Roche's Hivid and Invirase, as well as Anesta's Actiq and Dainippon Sumitomo Pharma America/Sunovion's Latuda. At Roche, the life-saving launch of Invirase therapy in less than 24 hours, working cooperatively with major wholesalers, received the HDMA DIANA award for this breakthrough thinking and record breaking release of Invirase to AIDS clinics. Carl is a sought out speaker at many industry conferences and speaks each semester at the Cornell University Enterprise Engineering Seminar.
Carl has earned a B.S. with distinction from Cornell University in Mechanical Engineering. He also holds a M.S. from University of Illinois and a M.B.A. from the Stern School at New York University.